Symbols / SEELQ $0.00 +0.00% Seelos Therapeutics, Inc.

Healthcare • Biotechnology • United States • PNK
SEELQ Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Raj Mehra J.D., Ph.D.
Exch · Country PNK · United States
Market Cap 58.00
Enterprise Value 9.86M
Income 4.09M
Sales 2.01M
FCF (ttm) -34.28M
Book/sh -135.50
Cash/sh 0.79
Employees 8
Insider 10d —
IPO Oct 31, 1994
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.00
Forward P/E —
PEG 3.41
P/S 0.00
P/B -0.00
P/C —
EV/EBITDA —
EV/Sales 4.90
Quick Ratio 0.02
Current Ratio 0.08
Debt/Eq —
LT Debt/Eq —
EPS (ttm) 0.20
EPS next Y —
EPS Growth —
Revenue Growth 11.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-11-14
Earnings (prior) 2023-11-14
ROA -261.11%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin -8.35%
Profit Margin 203.13%
Shs Outstand 581.00K
Shs Float 359.03K
Insider Own 11.15%
Instit Own 8.81%
Short Float 29.52%
Short Ratio 0.14
Short Interest 170.89K
52W High 0.01
vs 52W High -99.00%
52W Low 0.00
vs 52W Low 0.00%
Beta 22.99
Impl. Vol. —
Rel Volume 0.88
Avg Volume 114.00
Volume 100.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-1062.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
Operating Expense
40.50
-42.89%
70.92
+14.99%
61.67
Research And Development
30.12
-48.62%
58.62
+25.66%
46.65
Selling General And Administration
12.59
+2.35%
12.30
-18.14%
15.02
General And Administrative Expense
12.59
+2.35%
12.30
-18.14%
15.02
Other Gand A
12.59
+2.35%
12.30
-18.14%
15.02
Other Operating Expenses
-2.20
—
—
Total Expenses
40.50
-42.89%
70.92
+14.99%
61.67
Operating Income
-40.50
+42.89%
-70.92
-14.99%
-61.67
Total Operating Income As Reported
-40.50
+42.89%
-70.92
-14.99%
-61.67
EBITDA
-37.75
+48.62%
-73.47
-13.99%
-64.45
Normalized EBITDA
-40.24
+43.11%
-70.74
-14.92%
-61.56
Reconciled Depreciation
0.06
+7.55%
0.05
0.00
EBIT
-37.81
+48.58%
-73.52
-14.07%
-64.45
Total Unusual Items
2.49
+191.52%
-2.73
+5.84%
-2.89
Total Unusual Items Excluding Goodwill
2.49
+191.52%
-2.73
+5.84%
-2.89
Special Income Charges
-9.15
0.00
+100.00%
-2.24
Other Special Charges
9.15
—
2.24
Net Income
-37.88
+48.48%
-73.53
-11.33%
-66.05
Pretax Income
-37.88
+48.48%
-73.53
-11.33%
-66.05
Net Non Operating Interest Income Expense
0.12
+14.95%
0.11
+107.21%
-1.49
Interest Expense Non Operating
0.07
+435.71%
0.01
-99.12%
1.60
Net Interest Income
0.12
+14.95%
0.11
+107.21%
-1.49
Interest Expense
0.07
+435.71%
0.01
-99.12%
1.60
Interest Income Non Operating
0.20
+63.64%
0.12
+7.08%
0.11
Interest Income
0.20
+63.64%
0.12
+7.08%
0.11
Other Income Expense
2.49
+191.52%
-2.73
+5.84%
-2.89
Other Non Operating Income Expenses
-2.05
+32.08%
-3.02
-1411.74%
0.23
Gain On Sale Of Security
11.64
+527.34%
-2.73
-315.40%
-0.66
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-37.88
+48.48%
-73.53
-11.33%
-66.05
Net Income From Continuing Operation Net Minority Interest
-37.88
+48.48%
-73.53
-11.33%
-66.05
Net Income From Continuing And Discontinued Operation
-37.88
+48.48%
-73.53
-11.33%
-66.05
Net Income Continuous Operations
-37.88
+48.48%
-73.53
-11.33%
-66.05
Normalized Income
-40.38
+42.98%
-70.81
-12.12%
-63.15
Net Income Common Stockholders
-37.88
+48.48%
-73.53
-11.33%
-66.05
Diluted EPS
-989.44
+62.73%
-2,654.72
+5.30%
-2,803.20
Basic EPS
-989.44
+62.73%
-2,654.72
+5.30%
-2,803.20
Basic Average Shares
0.04
+38.20%
0.03
-92.69%
0.38
Diluted Average Shares
0.04
+38.20%
0.03
+17.03%
0.02
Diluted NI Availto Com Stockholders
-37.88
+48.48%
-73.53
-11.33%
-66.05
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Assets
5.42
-76.18%
22.75
-72.76%
83.50
Current Assets
5.40
-76.17%
22.67
-72.83%
83.46
Cash Cash Equivalents And Short Term Investments
3.00
-80.71%
15.53
-80.27%
78.73
Cash And Cash Equivalents
3.00
-80.71%
15.53
-80.27%
78.73
Cash Financial
3.00
-80.71%
15.53
-80.27%
78.73
Receivables
0.76
0.00
—
Accounts Receivable
0.76
0.00
—
Prepaid Assets
1.57
-77.42%
6.94
+52.89%
4.54
Other Current Assets
0.08
-61.50%
0.20
+6.95%
0.19
Total Non Current Assets
0.01
-79.17%
0.07
+84.62%
0.04
Net PPE
0.01
-79.17%
0.07
+84.62%
0.04
Gross PPE
0.01
-79.17%
0.07
+84.62%
0.04
Properties
0.00
0.00
0.00
Buildings And Improvements
0.01
-79.17%
0.07
+84.62%
0.04
Total Liabilities Net Minority Interest
38.93
+16.70%
33.36
+27.43%
26.18
Current Liabilities
38.93
+54.73%
25.16
+203.58%
8.29
Payables And Accrued Expenses
18.86
+59.65%
11.81
+173.62%
4.32
Payables
16.40
+181.79%
5.82
+207.50%
1.89
Accounts Payable
16.40
+352.37%
3.63
+114.18%
1.69
Other Payable
—
2.19
+997.50%
0.20
Current Accrued Expenses
2.46
-58.96%
5.99
+147.18%
2.42
Pensionand Other Post Retirement Benefit Plans Current
0.06
-95.65%
1.29
-1.15%
1.30
Current Debt And Capital Lease Obligation
14.23
+19.33%
11.92
+1016.39%
1.07
Current Debt
14.21
+19.79%
11.87
+1051.94%
1.03
Other Current Borrowings
14.21
+19.79%
11.87
+1051.94%
1.03
Current Capital Lease Obligation
0.01
-74.14%
0.06
+52.63%
0.04
Other Current Liabilities
5.78
+4279.55%
0.13
-91.74%
1.60
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
8.20
-54.17%
17.89
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
8.20
-54.17%
17.89
Long Term Debt
—
8.18
-54.25%
17.89
Long Term Capital Lease Obligation
0.00
-100.00%
0.01
0.00
Tradeand Other Payables Non Current
—
—
0.00
Stockholders Equity
-33.51
-215.80%
-10.61
-118.51%
57.32
Common Stock Equity
-33.51
-215.80%
-10.61
-118.51%
57.32
Capital Stock
0.01
+150.00%
0.00
-96.19%
0.10
Common Stock
0.01
+150.00%
0.00
-96.19%
0.10
Preferred Stock
0.00
0.00
0.00
Share Issued
0.08
+174.19%
0.03
+1.58%
0.03
Ordinary Shares Number
0.08
+174.19%
0.03
+1.58%
0.03
Additional Paid In Capital
219.11
+7.34%
204.13
+2.87%
198.43
Retained Earnings
-252.63
-17.64%
-214.74
-52.07%
-141.21
Total Equity Gross Minority Interest
-33.51
-215.80%
-10.61
-118.51%
57.32
Total Capitalization
-33.51
-1280.72%
-2.43
-103.23%
75.21
Working Capital
-33.52
-1249.64%
-2.48
-103.30%
75.17
Invested Capital
-19.30
-304.46%
9.44
-87.62%
76.24
Total Debt
14.23
-29.29%
20.12
+6.14%
18.96
Net Debt
11.22
+148.38%
4.52
—
Capital Lease Obligations
0.01
-79.45%
0.07
+92.11%
0.04
Net Tangible Assets
-33.51
-215.80%
-10.61
-118.51%
57.32
Tangible Book Value
-33.51
-215.80%
-10.61
-118.51%
57.32
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-23.91
+61.18%
-61.60
-25.74%
-48.99
Cash Flow From Continuing Operating Activities
-23.91
+61.18%
-61.60
-25.74%
-48.99
Net Income From Continuing Operations
-37.88
+48.48%
-73.53
-11.33%
-66.05
Depreciation Amortization Depletion
0.06
+7.55%
0.05
0.00
Depreciation
0.06
+7.55%
0.05
0.00
Depreciation And Amortization
0.06
+7.55%
0.05
0.00
Other Non Cash Items
6.35
+47.23%
4.31
-38.29%
6.99
Stock Based Compensation
3.99
-21.39%
5.07
-39.22%
8.35
Operating Gains Losses
-8.84
-2928.77%
-0.29
-109.35%
3.12
Gain Loss On Investment Securities
-18.00
-6062.67%
-0.29
-132.96%
0.89
Change In Working Capital
12.42
+346.25%
2.78
+297.80%
-1.41
Change In Receivables
-0.76
0.00
—
Change In Prepaid Assets
5.69
+353.09%
-2.25
+22.36%
-2.89
Change In Payables And Accrued Expense
7.55
+20.75%
6.25
+320.65%
1.49
Change In Accrued Expense
-4.22
-219.93%
3.52
+95.02%
1.81
Change In Payable
11.78
+330.92%
2.73
+956.74%
-0.32
Change In Account Payable
12.78
+560.99%
1.93
+1096.39%
-0.19
Change In Other Current Liabilities
-0.06
+95.27%
-1.23
0.00
Financing Cash Flow
11.38
+812.27%
-1.60
-101.43%
112.07
Cash Flow From Continuing Financing Activities
11.38
+812.27%
-1.60
-101.43%
112.07
Net Issuance Payments Of Debt
-7.64
-304.71%
-1.89
+86.07%
-13.55
Issuance Of Debt
—
—
0.00
Repayment Of Debt
-7.64
-304.71%
-1.89
+86.07%
-13.55
Long Term Debt Issuance
—
—
0.00
Long Term Debt Payments
-7.64
-304.71%
-1.89
+86.07%
-13.55
Net Long Term Debt Issuance
-7.64
-304.71%
-1.89
+86.07%
-13.55
Net Common Stock Issuance
18.92
+4039.82%
0.46
-99.61%
118.16
Common Stock Payments
-1.20
0.00
—
Repurchase Of Capital Stock
-1.20
0.00
—
Proceeds From Stock Option Exercised
0.10
-9.35%
0.11
-98.57%
7.46
Net Other Financing Charges
—
-0.27
—
Changes In Cash
-12.54
+80.16%
-63.20
-200.20%
63.07
Beginning Cash Position
15.53
-80.27%
78.73
+402.71%
15.66
End Cash Position
3.00
-80.71%
15.53
-80.27%
78.73
Free Cash Flow
-23.91
+61.18%
-61.60
-25.74%
-48.99
Interest Paid Supplemental Data
0.51
+4490.91%
0.01
+10.00%
0.01
Income Tax Paid Supplemental Data
0.00
0.00
0.00
Common Stock Issuance
20.11
+4301.31%
0.46
-99.61%
118.16
Issuance Of Capital Stock
20.11
+4301.31%
0.46
-99.61%
118.16
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category